drugset / Trial / NCT00928681
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
study to investigate the safety and efficacy properties of PF-00547659 in patients with active ulcerative colitis
Timeline
- Start
- 2005-09
- Primary completion
- 2008-04
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ontamalimab | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | Ontamalimab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Ontamalimab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Ontamalimab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Ontamalimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Ontamalimab | Monoclonal antibody | 10 mg/kg | Intravenous |